CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California.The CytRx oncology pipeline includes three programs in clinical development: bafetinib, tamibarotene and INNO-206. The company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia , a pharmacokinetic clinical trial in brain cancer and the PROACT Phase 2 clinical trial in advanced prostate cancer. With its tumor-targeting pro-drug candidate INNO-206, CytRx is conducting a safety trial with plans to initiate Phase 2 proof-of-concept clinical trials as a treatment for soft-tissue sarcomas and pancreatic cancer. CytRx's pipeline also includes tamibarotene, which it is testing in patients with non-small-cell lung carcinoma and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia .Arimoclomol is an experimental drug developed by CytRx. The orally administered drug is intended to treat amyotrophic lateral sclerosis , also known as Lou Gehrig's Disease.Steven Arthur Kriegsman is the President and CEO. Wikipedia.
News Article | December 11, 2016
— Kaposi Sarcoma Pipeline Market Companies Involved in Therapeutics Development are Aphios Corp, AstraZeneca Plc, Biogenomics Limited, Cannabis Science Inc, Cell Medica Ltd, CytRx Corp, Tumorend LLC and Vironika LLC> Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea. This research provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774112 The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774112 • The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease). • The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774112-kaposi-sarcoma-pipeline-review-h2-2016.html
News Article | November 28, 2016
This report studies Non-small Cell Lung Cancer in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering Bristol-Myers Squibb GlaxoSmithKline Menarini Sanofi ZIOPHARM Oncology Alchemia Amgen Apotex BioMarin Pharmaceutical CellAct Pharma Cerulean Pharma Cipla Cornerstone Pharmaceuticals Curis CytRx Eli Lilly Exelixis Fresenius Kabi Genentech Hikma Pharmaceuticals Hospira Intas Pharmaceuticals Karyopharm Therapeutics Kyowa Hakko Kirin Ligand Pharmaceuticals Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Non-small Cell Lung Cancer in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Surgery Radiofrequency ablation (RFA) Radiation therapy Chemotherapy Targeted therapies Immunotherapy Split by application, this report focuses on consumption, market share and growth rate of Non-small Cell Lung Cancer in each application, can be divided into Application 1 Application 2 Application 3 Global Non-small Cell Lung Cancer Market Research Report 2016 1 Non-small Cell Lung Cancer Market Overview 1.1 Product Overview and Scope of Non-small Cell Lung Cancer 1.2 Non-small Cell Lung Cancer Segment by Type 1.2.1 Global Production Market Share of Non-small Cell Lung Cancer by Type in 2015 1.2.2 Surgery 1.2.3 Radiofrequency ablation (RFA) 1.2.4 Radiation therapy 1.2.5 Chemotherapy 1.2.6 Targeted therapies 1.2.7 Immunotherapy 1.3 Non-small Cell Lung Cancer Segment by Application 1.3.1 Non-small Cell Lung Cancer Consumption Market Share by Application in 2015 1.3.2 Application 1 1.3.3 Application 2 1.3.4 Application 3 1.4 Non-small Cell Lung Cancer Market by Region 1.4.1 North America Status and Prospect (2011-2021) 1.4.2 Europe Status and Prospect (2011-2021) 1.4.3 China Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.4.5 Southeast Asia Status and Prospect (2011-2021) 1.4.6 India Status and Prospect (2011-2021) 1.5 Global Market Size (Value) of Non-small Cell Lung Cancer (2011-2021) 7 Global Non-small Cell Lung Cancer Manufacturers Profiles/Analysis 7.1 Bristol-Myers Squibb 7.1.1 Company Basic Information, Manufacturing Base and Its Competitors 7.1.2 Non-small Cell Lung Cancer Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.1.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.1.4 Main Business/Business Overview 7.2 GlaxoSmithKline 7.2.1 Company Basic Information, Manufacturing Base and Its Competitors 7.2.2 Non-small Cell Lung Cancer Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.2.3 GlaxoSmithKline Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.2.4 Main Business/Business Overview 7.3 Menarini 7.3.1 Company Basic Information, Manufacturing Base and Its Competitors 7.3.2 Non-small Cell Lung Cancer Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.3.3 Menarini Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.3.4 Main Business/Business Overview 7.4 Sanofi 7.4.1 Company Basic Information, Manufacturing Base and Its Competitors 7.4.2 Non-small Cell Lung Cancer Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.4.3 Sanofi Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.4.4 Main Business/Business Overview 7.5 ZIOPHARM Oncology 7.5.1 Company Basic Information, Manufacturing Base and Its Competitors 7.5.2 Non-small Cell Lung Cancer Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.5.3 ZIOPHARM Oncology Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.5.4 Main Business/Business Overview 7.6 Alchemia 7.6.1 Company Basic Information, Manufacturing Base and Its Competitors 7.6.2 Non-small Cell Lung Cancer Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.6.3 Alchemia Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.6.4 Main Business/Business Overview 7.7 Amgen 7.7.1 Company Basic Information, Manufacturing Base and Its Competitors 7.7.2 Non-small Cell Lung Cancer Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.7.3 Amgen Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.7.4 Main Business/Business Overview 7.8 Apotex 7.8.1 Company Basic Information, Manufacturing Base and Its Competitors 7.8.2 Non-small Cell Lung Cancer Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.8.3 Apotex Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.8.4 Main Business/Business Overview 7.9 BioMarin Pharmaceutical 7.9.1 Company Basic Information, Manufacturing Base and Its Competitors 7.9.2 Non-small Cell Lung Cancer Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.9.3 BioMarin Pharmaceutical Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.9.4 Main Business/Business Overview 7.10 CellAct Pharma 7.10.1 Company Basic Information, Manufacturing Base and Its Competitors 7.10.2 Non-small Cell Lung Cancer Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.10.3 CellAct Pharma Non-small Cell Lung Cancer Production, Revenue, Price and Gross Margin (2015 and 2016) 7.10.4 Main Business/Business Overview 7.11 Cerulean Pharma 7.12 Cipla 7.13 Cornerstone Pharmaceuticals 7.14 Curis 7.15 CytRx 7.16 Eli Lilly 7.17 Exelixis 7.18 Fresenius Kabi 7.19 Genentech 7.20 Hikma Pharmaceuticals 7.21 Hospira 7.22 Intas Pharmaceuticals 7.23 Karyopharm Therapeutics 7.24 Kyowa Hakko Kirin 7.25 Ligand Pharmaceuticals
News Article | November 29, 2016
LOS ANGELES, Nov. 29, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) today announced positive updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin compared to investigator's choice in patients with relapsed or refractory soft tissue sarcomas (STS). The s...
News Article | February 15, 2017
SOUTH PLAINFIELD, NJ--(Marketwired - Feb 9, 2017) - PolarityTE™, Inc. ( : COOL) today announced it has appointed Steve Gorlin to the Board of Directors. Mr. Gorlin has extensive experience building successful biotechnology companies, and is a leader in regenerative medicine, pharmaceutical drug and medical device research and development. "We are extremely excited to announce Steve Gorlin as a new member of the PolarityTE™ Board of Directors. With over 40 successful years in the field, he remains a leader and serial entrepreneur in regenerative medicine, biotechnology, and wound care. Having founded and managed a variety of cell therapy, pharmaceutical, and medical device companies, including MiMedx, EntreMed, Hycor, Medivation, Medicis and NantKwest, he is without a doubt a truly valuable innovator," said Denver Lough, MD, PhD, Chairman and CEO. Newly appointed board member, Steve Gorlin, remarked, "I could not be more enthusiastic to join the Polarity team and Board of Directors. I look forward to bringing the revolutionary regenerative technology of Polarity to every patient that it can benefit. Upon learning about the platform and team behind this company, I knew I was staring at a winner. The passion of Dr. Lough and his team is palpable, which is always a critical ingredient to any business endeavor, and especially in biotechnology. I understand why he and Dr. Swanson left their plastic surgery training program at Johns Hopkins to pursue this technology, because it is clear that they have the potential to impact many more lives with Polarity than they ever could achieve as surgeons." During December 2016 PolarityTE entered into an Agreement and Plan of Reorganization to acquire certain intellectual property rights developed by Dr. Lough. Completion of the acquisition is subject to a number of conditions, including stockholder approval. There can be no assurance that the conditions will be met or that the acquisition will be successful. The Acquisition, and our business generally, is subject to a number of risks that are more fully described under "Risk Factors" that appear in our filings and reports with the SEC. About Steve Gorlin Over the past 40 years, Mr. Gorlin has founded several biotechnology and pharmaceutical companies, including Hycor Biomedical, Inc. (acquired by Agilent), Theragenics Corporation, CytRx Corporation, Medicis Pharmaceutical Corporation (sold to Valeant for approximately $2.6 billion), EntreMed, Inc., MRI Interventions (MRIC), MiMedx, and Medivation, Inc. Mr. Gorlin has served on the Business Advisory Council to the Johns Hopkins School of Medicine and has previously served on The Johns Hopkins BioMedical Engineering Advisory Board. He also serves on the Board of the Andrews Institute. He founded a number of non-medical related companies, including Perma-Fix, Inc., Pretty Good Privacy, Inc. sold to Network Associates, Judicial Correction Services, Inc. sold to Correctional Healthcare, and NTC China. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children. He presently serves as the Vice Chairman of NantKwest, and serves on the Board of NTC China, Inc. About PolarityTE™, Inc. PolarityTE™, Inc. is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE™ platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE™ uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. More information can be found online at www.polarityte.com. Forward Looking Statements Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
CytRx | Date: 2013-12-13
The invention relates to reconstituted formulations comprising an anthracycline compound, ethanol, and water. The invention also relates to injectable compositions comprising the reconstituted formulation and Lactated Ringers solution. Additionally, the invention relates to methods of using the formulations and compositions.
CytRx | Date: 2010-06-25
A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
CytRx | Date: 2014-06-04
The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolvtically or enzymaticaily in the body of the patient in a pH-dependent manner.
News Article | March 2, 2017
NEW YORK, March 2, 2017 /PRNewswire/ -- In today's pre-market research, Stock-Callers.com presents these Biotech equities for review: Halozyme Therapeutics Inc. (NASDAQ: HALO), CytRx Corp. (NASDAQ: CYTR), Cara Therapeutics Inc. (NASDAQ: CARA), and Keryx Biopharmaceuticals Inc....
News Article | December 19, 2016
LOS ANGELES, Dec. 19, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ:CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel Levitt, M.D., Ph.D., the Company's...
News Article | November 11, 2016
LOS ANGELES, Nov. 11, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today presented a poster with updated interim results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with...